| abstract |
The present invention refers to compounds of the following formula (I) or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions containing them and to a process for the preparation of said compounds: Formula (I), wherein: R 1 is independently selected from hydrogen atom, amine group, monocyclic or bicyclic aliphatic, aromatic, heteroaliphatic or heteroaromatic ring, optionally substituted by one or more substituents selected from C 1 -C 4 alkyl optionally substituted by one or more halogen atom(s), halogen, C 1 -C 4 alkoxy or phenyl group, optionally substituted by C 1 -C 4 alkyl; R 2 is independently selected from monocyclic or bicylic aliphatic, heteroaliphatic, aromatic or heteroaromatic ring, C 1 -C 6 alkyl, alkenyl or alkynyl chain, optionally substituted by one or more substituents selected from C 1 -C 4 alkyl optionally substituted by one or more halogen atom(s), halogen, C 1 -C 4 alkoxy, cyano, C 1 -C 4 alkylthio, SO-C 1 -C 4 alkyl, SO 2 -C 1 -C 4 alkyl, N(C 1 -C 4 alkyl) 2 ; n is 1 or 2; preferably n is 1; m is 0, 1 or 2; preferably m is 0; R 3 and R 4 can be, independently, -H, -F, C 1 -C 4 alkyl, -OH, -OC 1 -C 4 alkyl; preferably they are both -H; X is O or S; R 5 is -H or -CH 3 optionally substituted by one or more fluorine atoms; preferably R 5 is hydrogen. The compounds of the invention can be used in the treatment of conditions or diseases mediated by P2X7 receptor. |